Bluejay Diagnostics Inc. Common Stock (BJDX)
Stock · NASDAQ · Health Care
$0.745as of 10/16/2026
Price chart
BJDX Signal Track Record
How signals performed across all stocks →What BJDX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 23 | -12.4% | 22% | July 29, 2026 |
| Volume Spike | 21 | -16.7% | 38% | October 6, 2026 |
| Bollinger Band Breakout | 16 | -16.4% | 19% | May 28, 2026 |
| Any 20-session window (baseline) | -13.9% | 27% |
Computed by MarketWall from daily closing prices since August 26, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BJDX
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 6
- Website
- bluejaydx.com/
Fundamentals
- 1-day range
- $0.783$0.8249
- Market cap
- $1.19M
- P/E (trailing)
- —
- P/E (forward)
- -2.56
- EPS (trailing)
- $-49.44
- Dividend yield
- —
- Beta
- 0.95
- Avg. volume
- 3.57M
Bluejay Diagnostics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BJDXBluejay Diagnostics Inc. Common Stock$0.745▼ 4.36%Market cap $1.19MP/E —$0.755$16.68
- BEATWHeartbeam Inc. Warrant$0.0031▼ 65.56%Market cap $1.19MP/E —$0.005$0.5601
- VTAKCatheter Precision Inc. Common Stock$0.84▼ 14.29%Market cap $977.1KP/E —$0.82$30.6
- PFSAProfusa Inc. Common Stock$0.931▼ 12.99%Market cap $686.5KP/E —$1.25$3,000
- AEMDAethlon Medical Inc. Common Stock$5.15▼ 2.28%Market cap $1.96MP/E —$1.41$35.95
- TNONTenon Medical Inc. Common Stock$2.7▼ 7.22%Market cap $1.99MP/E —$2.4$50.4
- TNONWTenon Medical Inc. Warrant$0.0054▼ 8.47%Market cap $85.3KP/E —$0.0038$0.043
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BJDX Bluejay Diagnostics Inc. Common Stock | $1.19M | — | $0.745 | ▼ 4.36% | $0.755$16.68 |
| BEATW Heartbeam Inc. Warrant | $1.19M | — | $0.0031 | ▼ 65.56% | $0.005$0.5601 |
| VTAK Catheter Precision Inc. Common Stock | $977.1K | — | $0.84 | ▼ 14.29% | $0.82$30.6 |
| PFSA Profusa Inc. Common Stock | $686.5K | — | $0.931 | ▼ 12.99% | $1.25$3,000 |
| AEMD Aethlon Medical Inc. Common Stock | $1.96M | — | $5.15 | ▼ 2.28% | $1.41$35.95 |
| TNON Tenon Medical Inc. Common Stock | $1.99M | — | $2.7 | ▼ 7.22% | $2.4$50.4 |
| TNONW Tenon Medical Inc. Warrant | $85.3K | — | $0.0054 | ▼ 8.47% | $0.0038$0.043 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis PatientsYahoo · 10/6/2026
- Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic ShockYahoo · 10/6/2026
- Bluejay Diagnostics Reports SYMON-II Baseline Data Showing Diverse Critically Ill Sepsis Population And Meaningful Mortality Events Supporting IL-6 Evaluation For 28-Day Mortality RiskBenzinga · 10/6/2026
Insider Activity
Insider Actions →- ZEIDMAN FRED S · August 17, 2026 · Grant100.0K
- Wurth Douglas Clark · August 17, 2026 · Grant100.0K
- Dey Svetlana · August 17, 2026 · Grant100.0K
- Dey Indranil · August 17, 2026 · Grant28.0K
- CHASE DONALD R · August 17, 2026 · Grant100.0K
- HRT FINANCIAL LP · July 10, 2026 · Sale34.9K @ $1.4
- HRT FINANCIAL LP · July 9, 2026 · Buy64.0K @ $1.51
Institutional Ownership
March 31, 2026
- Total shares held
- 58.8K
- Total value held
- $108.2K
- Institutional holders
- 6
- Unknown28.7K
- Unknown28.1K
- Unknown1.7K
- Unknown124
- Unknown120
- Unknown3
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Bluejay Diagnostics Shares SYMON-II Sepsis Trial Data
Bluejay Diagnostics released baseline data from its SYMON-II trial, highlighting a diverse group of critically ill sepsis patients with significant mortality events. This data supports the evaluation of IL-6 as a marker for 28-day mortality risk in rapid biomarker testing. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the clinical development of its diagnostic platform.
Bluejay Diagnostics Shares SYMON-II Sepsis Trial Data. Bluejay Diagnostics released baseline data from its SYMON-II trial, highlighting a diverse group of critically ill sepsis patients with significant mortality events. This data supports the evaluation of IL-6 as a marker for 28-day mortality risk in rapid biomarker testing. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the clinical development of its diagnostic platform.